Book contents
- Prescriber’s Guide – Children and Adolescents
- Prescriber’s Guide – Children and Adolescents
- Copyright page
- Contents
- Introduction
- List of icons
- Amphetamine-D
- Amphetamine-D,L
- Aripiprazole
- Asenapine
- Atomoxetine
- Bupropion
- Chlorpromazine
- Citalopram
- Clomipramine
- Clonidine
- Clozapine
- Duloxetine
- Escitalopram
- Fluoxetine
- Fluphenazine
- Fluvoxamine
- Guanfacine
- Haloperidol
- Lisdexamfetamine
- Lithium
- Lurasidone
- Methylphenidate-D
- Methylphenidate-D,L
- Olanzapine
- Paliperidone
- Paroxetine
- Pimozide
- Quetiapine
- Risperidone
- Sertraline
- Trazodone
- Valproate
- Venlafaxine
- Index by drug name (trade names and generic names)
- Index by use
- Index by class
- Abbreviations
- Endmatter
- References
Olanzapine
Published online by Cambridge University Press: 19 October 2021
Book contents
- Prescriber’s Guide – Children and Adolescents
- Prescriber’s Guide – Children and Adolescents
- Copyright page
- Contents
- Introduction
- List of icons
- Amphetamine-D
- Amphetamine-D,L
- Aripiprazole
- Asenapine
- Atomoxetine
- Bupropion
- Chlorpromazine
- Citalopram
- Clomipramine
- Clonidine
- Clozapine
- Duloxetine
- Escitalopram
- Fluoxetine
- Fluphenazine
- Fluvoxamine
- Guanfacine
- Haloperidol
- Lisdexamfetamine
- Lithium
- Lurasidone
- Methylphenidate-D
- Methylphenidate-D,L
- Olanzapine
- Paliperidone
- Paroxetine
- Pimozide
- Quetiapine
- Risperidone
- Sertraline
- Trazodone
- Valproate
- Venlafaxine
- Index by drug name (trade names and generic names)
- Index by use
- Index by class
- Abbreviations
- Endmatter
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Prescriber's Guide – Children and AdolescentsStahl's Essential Psychopharmacology, pp. 351 - 366Publisher: Cambridge University PressPrint publication year: 2018
References
Suggested Reading
Kryzhanovskaya, L, Schulz, SC, McDougle, C et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(7):60–70.CrossRefGoogle ScholarPubMed
Lytle, S, McVoy, M, Sajatovic, M. Long-acting injectable antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol 2017;27(1):2–9.CrossRefGoogle ScholarPubMed
Pillay, J, Boylan, K, Carrey, N et al. First- and second-generation antipsychotics in children and young adults: systematic review update [internet]. Comparative Effectiveness Reviews. AHRQ Publication No. 17-EHC001-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2017.Google Scholar
Stentenbjerg-Olesen, M, Ganocy, SJ, Findling, RL et al. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur Child Adolesc Psychiatry 2015;24(12):1485–96.Google Scholar